Cidara Therapeutics Inc. (CDTX)
22.46
0.88 (4.08%)
At close: Mar 28, 2025, 3:59 PM
22.82
1.60%
Pre-market: Mar 31, 2025, 04:35 AM EDT
Cidara Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 1.27M | 63.91M | 64.29M | 49.57M | 12.07M | 20.91M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 84.88M | 1.52M | 143K | 189K | 68.02M | 46.4M | 523K | 667K | 732K | 461K | n/a | n/a | n/a |
| Gross Profit | -83.61M | 62.38M | 64.14M | 49.38M | -55.95M | -25.49M | -523K | -667K | -732K | -461K | n/a | n/a | n/a |
| Operating Income | -176.1M | -24.48M | -29.72M | -42.26M | -71.85M | -41.72M | -63.28M | -55.72M | -48.44M | -32.31M | -11.62M | -1.08M | -792K |
| Interest Income | 5.81M | 2M | 191K | 212K | 262K | 221K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -170.29M | -22.49M | -29.53M | -42.47M | -72.11M | -41.09M | -59.02M | -55.73M | -48.16M | -32.19M | -11.89M | -1.34M | -792K |
| Net Income | -169.83M | -22.93M | -29.8M | -43.91M | -72.37M | -40.09M | -59.02M | -55.73M | -48.16M | -32.19M | -11.89M | -1.34M | -792K |
| Selling & General & Admin | 20.61M | 18.33M | 18.49M | 18.74M | 15.9M | 16.24M | 14.14M | 12.9M | 12.74M | 8.84M | 3.31M | 272K | 780K |
| Research & Development | 71.88M | 68.53M | 75.52M | 73.09M | 68.02M | 46.4M | 49.14M | 42.82M | 35.7M | 23.48M | 6.71M | 810K | 12K |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | -211K | n/a | n/a | n/a | -183K | -167K | n/a |
| Operating Expenses | 92.49M | 86.86M | 94.01M | 91.83M | 83.92M | 62.64M | 63.28M | 55.72M | 48.44M | 32.31M | 10.02M | 1.08M | 792K |
| Interest Expense | n/a | n/a | 191K | 212K | 262K | 221K | 629K | 7K | 271K | 120K | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 177.38M | 88.39M | 94.01M | 91.83M | 83.92M | 62.64M | 63.28M | 55.72M | 48.44M | 32.31M | 10.02M | 1.08M | 792K |
| Income Tax | n/a | 443K | 272K | 1.44M | 262K | -1.01M | 4.27M | -667K | -732K | -461K | 1.7M | -987K | n/a |
| Shares Outstanding (Basic) | 6.35M | 4.37M | 3.49M | 2.62M | 2.08M | 1.5M | 1.29M | 875.04K | 724.45K | 688.48K | 40.99K | 16.18K | 17.72K |
| Shares Outstanding (Diluted) | 6.35M | 4.37M | 3.49M | 2.62M | 2.08M | 1.5M | 1.29M | 875.04K | 724.45K | 688.48K | 40.99K | 16.18K | 3.12M |
| EPS (Basic) | -26.82 | -5.25 | -8.53 | -16.75 | -34.83 | -26.78 | -45.62 | -63.69 | -66.49 | -46.76 | -290.15 | -83.04 | -44.7 |
| EPS (Diluted) | -26.82 | -5.25 | -8.53 | -16.74 | -34.83 | -26.78 | -45.62 | -63.69 | -66.49 | -46.76 | -290.15 | -83.04 | -0.25 |
| EBITDA | -176.1M | -24.36M | -33.36M | -42.26M | -71.56M | -41.4M | -62.76M | -55.72M | -47.7M | -31.85M | -9.84M | -1.08M | n/a |
| Depreciation & Amortization | n/a | 118K | 143K | 189K | 286K | 328K | 523K | 667K | 732K | 461K | 179K | 1.08M | 792K |